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Pancreatic lipase inhibitory activity of selected 
pharmaceutical agents
Twenty-five structurally diverse compounds have been tested 
in vitro for their pancreatic lipase (PL) inhibitory activity. 
Despite the diversity of tested compounds, the relationship 
comprising structural attributes of the compounds could be 
established to correlate with the observed inhibitory activity. 
Compounds that exerted inhibitory action through surface 
activity were of different profile from the rest of compounds. 
When co-incubated with orlistat (OsT), important synergistic 
effects for some compounds (orphenadrine, gliclazide, cefu-
roxime and sulfacetamide) were revealed, while antagonistic 
effects were demonstrated for others (camphor sulfonic acid 
and dinitro salicylic acid). Docking studies for the most active 
molecules were performed and molecular interaction forces 
with the PL active site were identified. The results suggested 
co-binding of OsT along with the other inhibitor in the bind-
ing site in cases of synergistic effect but not in the case of 
antagonistic effect. These results were additionally supported 
by affinity capillary electrophoresis. In conclusion, synergis-
tic lipase inhibitory activity between OsT and some other 
pharmaceutical compounds was demonstrated for the first 
time, which might help improve the pharmacological effect 
of OsT.
Keywords: pancreatic lipase, pancreatic lipase inhibitory 
test, pharmaceutical compounds, affinity capillary electro-
phoresis, docking studies
Pancreatic lipase (PL) is the main enzyme responsible for the breakdown of fatty tria-
cylglycerol to smaller components within the digestive system to enable their absorption. 
Compounds that may inhibit the action of PL are expected to have favorable effects in 
minimizing the amount of absorbed fat and consequently a positive effect on general 
health (1–3). The most direct application of such compounds might be their use as anti-
obesity drugs, because they may limit the amount of fatty material absorbed. In spite of 
the great public demand for such medicines, there has been only one effective PL inhibitor 
available in the market – orlistat (OsT). In recent years, interest in developing more effec-
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tive and safe inhibitors seems to have increased. There has been a fair number of reports 
that described the synthesis or isolation of new PL inhibitors, many of which exhibited 
only modest activity compared to OsT (4–8). PL is a rather complex enzyme whose activity 
is controlled by quite a number of factors such as the substrate, the product, pH of medium, 
metal ions and accessibility to the usually lipophilic substrate (1, 9–11). Surfactants, repre-
sented in the body by biliary secretion, usually play a significant role in the action of PL in 
that they improve the interfacing between aqueous medium and essentially lipophilic 
substrates (11–14). Moreover, PL was shown to have a special protein moiety that functions 
like a lid for the binding site, which can be open upon a trigger by the presence of an oily 
substrate (10, 11, 14). Co-lipase is another protein subunit necessary for optimal action of 
PL in the presence of bile acids, which may otherwise inhibit the lipolytic action of the 
enzyme (10). Such multiple factors make it difficult to precisely control or predict the activ-
ity of PL in vivo. Nevertheless, the three-dimensional structure of PL and its catalytic bind-
ing site have been characterized using X-ray crystallography when the binding site was 
shown to be composed of an aspartic acid-histidine-serine catalytic triad (1). In attempts 
to further explore the binding site of PL, twenty-five pharmaceutical compounds, most of 
them in clinical use, have been tested as PL inhibitors. In a previous report, the well-
known antibiotic tetracycline was found to possess an interesting alpha amylase inhibi-
tory activity, which helped explain some of its side effects (15). Therefore, in addition to 
identifying new structural scaffolds for lipase inhibitors, some of the side effects of com-
monly used drugs might be explained by this study as well.
EXPERIMENTAL
Chemicals, instruments and software
The tested pharmaceutical compounds (Table I) were kind gifts from the Jordanian 
Pharmaceutical Manufacturing Company (JPM, Jordan) and Dar Al Dawa Co. Ltd. (DAD, 
Jordan). All tested compounds were certified to be of > 98 % purity. All reagents and chemi-
cals, including porcine pancreatic lipase PL (type II), the substrate p-nitrophenyl butyrate 
(PNPB), Tris-HCl buffer and phosphate buffer were procured from Sigma-Aldrich Co. Ltd. 
(UK). A UV-VIS spectrophotometer (SpectroScan 80D, Sedico Ltd, UK) was used. Affinity 
capillary electrophoresis (ACE) experiments were performed using an Agilent CE 1000 
(Germany) instrument and electropherograms were monitored at 205 nm. Uncoated fused 
silica capillaries were obtained from Composite Metal Services Ltd. (UK) and were used 
after being cut to proper length without further modifications.
The following software packages were utilized in the docking experiments: i) CS 
ChemDrawUltra 12.0.2, Cambridge Soft Corp. (http://www.cambridgesoft.com), USA; ii) 
OMEGA (Version2.5.1.4); iii) OpenEye Scientific Software (www. eyesopen.com), USA; iv) 
FRED (Version 2.2.5), OpenEye Scientific Software, (www.eyesopen.com, USA); v) BIOVIA 
Discovery Studio visualizer 4.5, 2015, Biovia, Accelrys Inc. (www.accelrys.com, USA).
Spectrophotometric quantification of pancreatic lipase
All tested compounds were dissolved in DMSO to prepare a stock solution (of each 
compound) having a concentration in the range of 2–5 mg mL–1. A proper aliquot of the so 
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obtained solution was further diluted using 2.5 mmol L–1 Tris-HCl buffer, pH 7.4 (contain-
ing 2.5 mmol L–1 NaCl) to give a series of solutions with final drug concentrations in the 
range of 0.2–2000 μg mL–1, so that a dose response curve could be established. A stock 
solution of OsT, the reference drug, was also prepared in DMSO at a concentration of 1 mg 
mL–1. Proper aliquots of the so obtained solution were further diluted in Tris-HCl buffer 
(as above) to obtain standard solutions of OsT in the range 0.0125–0.4 μg mL–1. In vitro en-
zymatic pancreatic lipase (PL) activity was assayed according to a previously established 
procedure (16). Porcine pancreatic lipase was suspended in Tris-HCl buffer (as above) to 
give a concentration of 200 unit mL–1. The substrate, p-nitrophenyl butyrate (PNPB), was 
dissolved in acetonitrile to obtain a solution with a concentration of 100 μmol L–1. An ali-
quot (0.10 mL) of PL solution was added to the reaction mixture. The volume was com-
pleted to 1 mL using Tris-HCl buffer before measuring the solution absorbance spectro-
photometrically, at 410 nm, and after incubation for 5 min. The reaction, maintained at 37 
°C, was started by adding the substrate to the reaction mixture. Release of p-nitrophenol 
was measured as the increase in absorbance measured at 410 nm against a blank using 
denatured enzyme. PL was pre-incubated with each particular drug for at least 10 min at 
37 °C before adding the substrate. Percentage of residual activity of PL was determined for 
each test compound by comparing the lipase activity of PL with and without extract.
Subsequent determinations were undertaken for the tested compounds and OsT in 
comparison with the controls (denatured enzyme) to calculate percentage inhibition at 
each concentration and eventually the 50 % PL inhibition (IC50). The values are presented 
as mean ± standard deviation of 3 independent experiments. Once IC50 value for each 
compound was obtained, the PL inhibitory activity of each compound was also deter-
mined in the presence of OsT at a concentration level equal to the IC25 value for each drug 
and OsT. The purpose of this last experiment was to get a better understanding of how the 
presence of more than one potential inhibitor might influence the binding to PL and the 
subsequent inhibitory effect, e.g., synergistic or antagonistic.
Capillary electrophoresis
In our experimental design, samples of PL were always electrophoresed in phosphate 
buffer (pH 6.8), either alone or containing OsT or containing a test compound or containing 
a mixture of both OsT and the test compound. The idea behind the experimental protocol 
was to examine if any indication of OsT co-binding along with the other test compound 
could be obtained through shifts in migration times of the peaks or peak shape.
To dissolve PL for the enzyme inhibition test, a mixture was prepared of DMSO, phos-
phate buffer (50 mmol L–1, pH 6.8), methanol and calcium chloride solution (0.25 mg mL–1) 
in a volume ratio 1/40/10//9 (V/V/V/V). PL samples were prepared by dissolving 10 mg of the 
enzyme in 30 mL of the mixture described above. A 100-μL aliquot of the so obtained solu-
tion was mixed with 200 μL of methanol and vortex mixed before being injected into the 
affinity capillary electrophoresis (ACE) system as a PL alone sample. Samples of PL with test 
drug were prepared by mixing 100 μL of the original PL solution with 100 μL of drug solu-
tion and 100 μL of methanol. Samples of a test drug with OsT were prepared by mixing 100 
μL of the original PL solution, 100 μL of the test drug and 100 μL of OsT solution (400 μg mL–1 
in methanol). Electrophoresis running buffer consisted of 15 % acetonitrile and 16.7 % metha-
nol in 50 mmol L–1 phosphate buffer (pH 6.8), which was marked as blank running buffer. In 
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cases where a test drug had to be added to the buffer, 1 mL of blank running buffer was 
mixed with 100 μL of the test drug solution (400 μg mL–1 in methanol) and 100 μL of metha-
nol. When the running buffer had to contain both the test drug and OsT, 1 mL of blank run-
ning buffer was mixed with 100 μL of the test drug solution (400 μg mL–1 in methanol) and 
100 μL of OsT solution (400 μg mL–1 in methanol). Electrophoresis of all samples was per-
formed using uncoated fused silica capillaries cut to a length of 55 cm (75 mm i.d.) with an 
operating voltage of 15 kV. All electropherograms were monitored at 205 nm. Samples were 
injected electrokinetically for 15 s at 18 kV. Each injection was preceded by flushing for 30 s 
with 0.1 mol L–1 NaOH for 30 s with water and finally 2 min running buffer fill.
Docking experiments
The docking study was conducted utilizing a docking engine FRED (FRED 2009). 
FRED docks molecules employing a comprehensive search algorithm where it systemati-
cally searches rotations and translations of each conformer of the ligand within the active 
site and filters unrealistic poses. Pose generation is followed by estimating the strength of 
ligand-target interactions (scoring) to guide conformational sampling and estimating the 
biological activity. Final docked conformations (poses) are ranked and selected according 
to their scores. For PL, we had previously identified the optimal docking configuration and 
scoring function by the self-docking of the co-crystallized ligand. These parameters were 
further validated experimentally when they were used to estimate the bioactivity of some 
natural and synthetic PL inhibitors and were predicted by simulated docking to bind 
within the PL active site.
The 2D chemical structures of docked compounds (Fig. 2) were sketched in Chem-
draw Ultra (12.0.2) and saved in the MDL molfile format. Subsequently, a group of ener-
getically accessible conformers was generated using OMEGA software (OMEGA, 2013; 
Version2.5.1.4), OpenEye Scientific Software (www. eyesopen.com, USA). OMEGA rapidly 
generates conformational ensembles of small molecules using a fragment-based library in 
order to build initial models of structures by assembling these fragment templates fol-
lowed by a rule-based torsion search stage. The generated conformers were saved in the 
SD format. The 3D geometry of pancreatic lipase (PL) was retrieved from the Protein Data 
Bank (PDB code: 1LPB, resolution 2.46 Å) (10). Hydrogen atoms were added to the protein 
using the BIOVIA discovery studio visualizer templates (Discovery Studio visualizer 4.5, 
2015 Biovia, Accelrys Inc. (www.accelrys.com,USA) for protein residues. No energy mini-
mization for the protein structure was done. The docking study was conducted in the 
presence of explicit water molecules. Test compounds (Fig. 2) were docked into the binding 
pocket of PL using the FRED (FRED (Version 2.2.5), OpenEye Scientific Software, (www.
eyesopen.com, USA) software. Ligand conformers and protein structure are treated as 
rigid entities during the docking process. FRED docking roughly consists of 2 steps: shape 
fitting and optimization. In the fitting phase, the ligand is placed into a grid box including 
all active-site atoms, then a series of three optimization filters are employed (optimization 
phase). The filters include rigid body optimization, refining the position of the ligand hy-
droxyl hydrogen atoms and finally optimization of the ligand pose in the dihedral angle 
space (FRED 2009; FRED (Version 2.2.5), OpenEye Scientific Software, (www.eyesopen.
com, USA). Generated conformers of the test compounds were used as input to the FRED 
software. Docking settings that succeeded in reproducing the experimental pose of the 
co-crystallized ligand (MUP901, C11P) were employed (10). Our previously optimized 
FRED docking simulation parameters for pancreatic lipase have been reported (17).
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RESULTS AND DISCUSSION
Lipase inhibitory activity
The obtained IC50 value for OsT was 0.2 ± 0.01 μmol L–1, which is comparable to IC50 
values reported elsewhere (18), thus promoting the validity and reliability of the recruited 
PL activity assay. Comparable to OsT performance, a marked concentration dependent PL 
inhibition trend was obtained for various test drugs. The obtained IC50 values for the tested 
compounds are presented in Table I. While 8 of the 25 tested compounds were shown to 
have reasonable lipase inhibitory activity, 7 had no detectable activity under the employed 
assay conditions, which served as a negative control that helped in validating our results.
Some of the tested compounds were shown for the first time to have reasonable PL 
inhibitory activities, e.g., orphenadrine (OrP) and gliclazide (GzD). The most active com-
pounds exhibited IC50 values in the range of 20–50 μmol L–1, which obviously could not 
mount to the activity of the standard inhibitor OsT, but is quite comparable to the range of 
IC50 values reported for naturally occurring and synthetic lipase inhibitors (3). The list of 
most active compounds with IC50 < 50 μmol L–1 included acetylsalicylic acid (AsA), cam-
phor sulfonic acid (CsA), dinitro salicylic acid (DnS), gamma-anilino naphthalene sul-
fonic acid (GsA), gliclazide (GzD), orphenadrine (OrP), salicylic acid (ScA) and sulfaceta-
mide (SfD). From the above mentioned compounds, only ScA had been previously 
reported to have a lipase inhibitory activity, which was previously investigated as lipase 
inhibitor along with other phenolic acids (19). One report has shown the ability of acetyl-
salicylic acid to improve the lipid profile for high fat-fed rats but attributed this effect to the 
influence on liver enzymes (20).
Therefore, we herein provide direct evidence that the effect of AsA might be, at least 
partly, mediated by its ability to inhibit PL. DnS was the most active compound with IC50 
value of 20.4 μmol L–1. In accordance with the previous reports and consequent predic-
tions, it was logical to observe lipase inhibitory activity for simple aromatic acids: DnS, 
Fig. 1. Plot of log IC50 against the activity predictor value (A).
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AsA and ScA (19, 21). Most interesting perhaps was the PL inhibitory activity of the sulfo-
nylurea drug GzD, the sulfonamide SfD and the basic drug OrP, which had not been previ-
ously reported to have such an activity. Short term use of GzD by diabetic patients was 
shown to improve postprandial lipemia (22), which might support our findings. More 
relevant, perhaps, were some recent reports which demonstrated the inhibition of the re-
lated enzyme diacylglycerol lipase by glycine sulfonamide derivatives that can be struc-
turally related to GzD and SfD (23, 24). Thus, our findings support the potential impor-
tance of sulfonamides or sulfonylurea derivatives as inhibitors of PL. OrP, a basic 
compound, represents a structurally unusual lipase inhibitor as many of the reported in-
hibitors were based on carboxylic acid or phenol function (5, 7, 19, 25). It was interesting to 
observe the lower activity of surfactants like sodium dodecyl sulfate (SdS) and sodium 
dioctylsulfonate (DoS). Surfactants have been reported to have a complex effect on lipase 
activity as they affect various equilibria that are relevant to the lipolytic activity of the 
enzyme (12). For example, their attachment to the surface of the oily substrate through 
their lipophilic tails forms a shield that hinders the access of PL to the oil/water interface. 
On the other hand, surfactants increase the solubility of the substrate, which may enhance 
the lipolytic action of the enzyme.
Structure-activity studies
Another interesting inhibitory compound was aspartic acid (AsP). Although AsP did 
not exhibit particularly high inhibitory activity (IC50 = 91.7 μmol mL–1), it had a slightly 
polar structure, which is rather unusual for a lipase inhibitor. Therefore, attempts were 
made to better understand the correlation between structural features and PL inhibitory 
activity. Several algorithms were randomly generated in an effort to find a possible correla-
tion with the observed lipase inhibitory activities, using molecular descriptors such as log 
P, pKa, number of hydrogen bonds acceptors, number of hydrogen bonds donors, rotatable 
bond count and polar surface area. Eventually, an algorithm that reasonably correlates the 
Fig. 2. Chemical structures of the seven most active compounds: gliclazide (GzD), gamma-anilino 
sulfonic acid (GsA), camphor sulfonic acid (CsA), orphinadrine (OrP), dinitrosalicylic acid (DnS), 
acetyl salicylic acid (AsA) and sulfacetamide (SfD).
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observed in vitro inhibitory effect of a compound with its molecular descriptors was ob-
tained, and is given by the equation:
A = [(log P + pKa)/(P + Hd + Ha)] × [(Rb × PSA)/com]
where A is the estimated activity predictor, P is the partition coefficient, Hd is the number 
of hydrogen bond donors, Ha is the number of hydrogen bond acceptors, Rb is the number 
of rotatable bonds, PSA is the polar surface area and com is complexity. It is interesting 
that, when log IC50 was plotted against the A value, and excluding inactive compounds, 
cefuroxime axetil (CfA) and uric acid (UrA) (Table I), two clear linear relationships could 
be distinguished (Fig. 1). Seemingly, one of them reflected the lower activity group of 
compounds while the other reflected more active compounds, but both exhibited good 
determination coefficients of 0.85 and 0.99, respectively. Thus, we proposed that the tested 
group of compounds bind in two different modes to the enzyme, leading to its inhibition. 
Consequently, two distinct linear relationships were observed. Interestingly, the low activ-
ity group of inhibitors included compounds such as AsP and diethylbarbituric acid (DbS) 
(Table I) that do not possess the typical features of PL inhibitors, e.g., phenol or carboxylic 
acid. On the other hand, the more active group included compounds with typical struc-
tural requirements for PL inhibitory activity, e.g., ScA, AsA in addition to new structural 
nuclei reported in this study only, i.e., OrP, GzD and SfD.
In order to gain a better insight into the binding modes of the examined inhibitors, 
two studies were conducted. In one, the inhibitory activity was assessed for each com-
pound in the presence of the standard inhibitor OsT, both at IC25. The reason was that, if 
there was no interaction between the binding process/mode of OsT and that of the inhibi-
tor being tested, then the observed inhibition percentage would consistently be ~50 %. 
Percentages higher than 50 % would indicate synergism in the action of the two drugs and 
most probably different interaction/binding modes with the active site of the enzyme. 
Some of the tested compounds exhibited a negative value of inhibition when tested in the 
presence of OsT, thus suggesting some degree of enzymatic activation rather than inhibi-
tion, with DoS having the most obvious effect (–16 %). Careful examination of these com-
pounds revealed that they all shared some degree of surface activity as they are composed 
of a polar ionized part (sulfonic or carboxylic) and another lipophilic part. Therefore, the 
observed enzyme activation when combined with OsT could be understood as surfactants 
increasing the effective concentrations of both the enzyme and the substrate (12–14). Being 
a highly lipophilic molecule with a positively charged polar head, OsT was potentially 
inactivated in the presence of the negatively charged micelle molecules by being impeded 
within the micellar structure, i.e., forming mixed micelles as previously reported with bile 
salts (11). A few other compounds, e.g., DnS and cephalexin (CpL), demonstrated low posi-
tive values (0–20 %) of inhibition, which indicates antagonistic rather than synergistic ac-
tion with OsT. The result for DnS was particularly interesting because it exhibited the 
lowest IC50 in the absence of OsT but demonstrated obvious antagonism in its presence.
Compounds that exhibited an inhibition effect within ± 20 % of the expected value of 
50 %, (e.g., AsA, AvS and ScA) were considered to behave according to expectations, i.e., they 
simply showed an additive effect with OsT, suggesting that they may bind to the enzyme in 
a similar manner as to OsT. On the other hand, a fair number of compounds (GzD, OrP, UrA, 
AsA, MfA, DbS, SfD and CfA) appeared to have a synergistic effect with OsT, with obtained 
activities > 80 % and in some cases > 90 %. It is noteworthy that even compounds with very 
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low activities on their own, like DnS and CfA, were shown to substantially enhance the OsT 
activity. These observations suggest that the tested compounds with synergistic effects bind 
to the enzyme in different modes with consequent closure of some parts of the active site, 
but exposure of OsT binding site and enhanced activity. On the other hand, the binding of 
compounds (with antagonistic activity) may result in obstruction of the OsT binding site; 
therefore, they may exhibit a reasonable inhibitory activity when present alone but the over-
all activity would be diminished when present together with OsT. Our findings could help 
explain potential drug-drug interaction side effects through their synergistic or antagonistic 
action with OsT. Attempts were, however, made to further explore the mechanism by which 
different inhibitors interact with the enzyme.
Docking studies
Simulated molecular docking is basically a conformational sampling procedure in 
which various docked poses/conformations are explored to identify the correct one (26, 27). 
Therefore, the seven most active test compounds (Fig. 2) were docked into the binding pock-
et of PL with the binding site being defined from the crystallographic structure of a bound 
high-affinity ligand (MUP901, C11P). Fig. 3 shows the highest ranking pose for the most 
active compounds when docked within the binding site of PL along with the scoring func-
tion calculated using Chemgauss according to their binding affinities. Some similarities 
were noticed in the binding profiles between the self-docked ligand (MUP901, C11P) and 
some of the tested drugs. GzD, which exhibited the highest estimated affinity, fitted nicely 
within the PL binding pocket. The benzene ring of GzD undergoes many hydrophobic in-
teractions of aromatic π–π (pi-pi) stacking and π-alkyl with several key amino acid residues, 
including Phe-77, Phe-215, Tyr-114 and Pro-180, which collectively form a lipophilic pocket 
within the binding pocket of PL. Other hydrophobic attractions occurred with His-263 and 
Leu-264 amino acid residues, in addition to two hydrogen bonds formed with Phe-77 amino 
acid which stabilized the ligand-protein complex, as shown in Fig. 3a. GsA was ranked sec-
ond to GzD and also underwent aromatic π–π stacking between its naphthalene ring and 
Tyr-114 residue in addition to π-alkyl with Pro-180. Similarly to GzD, hydrophobic attraction 
occurred with His-263 amino acid residue (Fig. 3b). It is, however, noteworthy that both of 
these compounds (GzD and GsA) missed interaction with Ser-152, which had previously 
been shown to be very significant for inhibition to take place (28). This might account for the 
observation that despite their exhibiting the highest Chemgauss score rank, they were not 
the most active inhibitors according to the in vitro lipase inhibitory test results. The impor-
tance of interaction with the Ser-152 residue was reinforced with the binding of DnS, where 
it appeared to form two strong hydrogen bonds with Ser-152 and another weaker with Pro-
180, in addition to two hydrophobic π–π stacking interactions between its aromatic ring and 
both of Phe-215 and Tyr-114 amino acid residues. Experimentally, DnS exhibited the best 
inhibitory activity among all the tested compounds, which is in accord with its observed 
high degree of interaction with the active site including Ser-152. However, DnS and CsA 
were ranked next to GzD and GsA according to the Chemgauss score. CsA also formed 
many hydrophobic π-alkyl interactions with the hydrophobic side and the aromatic rings of 
Phe-77, Phe-215 and Tyr-114 amino acid residues, and three hydrogen bonds with Ser-152, 
His-263 and Phe-77, which appeared to stabilize the ligand-protein complex, thus explaining 
the observed high activity of CsA. On the other hand, OrP underwent only hydrophobic 
stacking interactions (aromatic π–π stacking and π-alkyl stacking) between its benzene/
11
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benzyl rings and Phe-215, Tyr-114, His-263, Pro-180 and Ala-178 amino acid residues of PL 
and was thus in accord with the observed relatively higher IC50 for OrP.
AsA and SfD demonstrated a considerable number of tight interactions with the en-
zyme binding site, in accordance with their observed lowest IC50 value range. AsA formed 
three hydrogen bonds with Ser-152, Tyr-114 and a weaker one with Pro-180 amino acids, 
but it only formed one hydrophobic aromatic π–π stacking with Tyr-114 residue. With SfD, 
the amine group of the aniline ring formed two strong hydrogen bonds with Ser-152 and 
Phe-215 while its aromatic ring underwent three hydrophobic interactions of aromatic π–π 
stacking and π-alkyl with Tyr-114, Pro-180 and Ala-178. Although no exact quantitative 
relationship was obtained from docking studies to describe the in vitro inhibitory activity, 
they provided some semi-quantitative explanations of the observed trends in inhibitory 
activities. For example, the two least active compounds were the ones shown not to be 
capable of hydrogen bonding with the crucial Ser-152 in the active site. On the other hand, 
the remaining 4 out of 7 compounds that were shown to be relatively highly active were 
confirmed to bind to Ser-152 through strong hydrogen bonding.
The possible explanation why DnS and CsA in particular, in the group of relatively 
highly active compounds, led to antagonism rather than synergism with OsT, and accord-
ing to the results provided by docking experiments, we may conclude the following: if the 
ligand is bulky enough to physically obstruct the binding site, and additionally tightly 
attach through Ser residue in particular, then there would be a minimal chance for OsT to 
reach the binding site and consequently its inhibitory activity would be antagonized (as 
with DnS and CsA; Fig. 3). On the other hand, if it cannot bind to Ser residue (even if it is 
bulky), or if it is not bulky enough, then there would be a space for OsT to reach the active 
site and accomplish its inhibitory action, which might be even potentiated by the addi-
tional binding of the test ligand (Fig. 3). In search for further support, simple experiments 
employing affinity capillary electrophoresis were performed.
Affinity capillary electrophoresis
Affinity capillary electrophoresis has been widely used in the studies of ligand-pro-
tein interactions (29). The obtained electropherograms (e-grams) showed that the presence 
of OsT in the running buffer caused an obvious shift in migration time (tm) and the peak 
shape change of PL (Fig. 4), thus pointing to the possible binding to the enzyme. However, 
the direction of change in tm (increase from 5.6 to 6.5 min) was rather unexpected because 
OsT exists as a positively charged molecule under the employed conditions, and its bind-
ing to the enzyme would impart a more positive charge, leading to faster mobility to the 
cathode (detector end) and thus lower tm.
Hence, it appears that binding of OsT to the enzyme induces some conformational 
changes in the enzyme three-dimensional structure that favors mobility in the opposite 
direction (anode). As electroosmotic flow (EOF) is larger than the intrinsic mobility of PL, 
it manages to reverse the direction of migration of the enzyme, but after an additional 
delay in tm. These results are in accord with previous reports that confirmed the occur-
rence of inhibitor-induced structural changes that were mainly opening of the lid loop, 
making it closer to the co-lipase part potentiating its association with PL, i.e., creating a 
more condensed structure (30). When incorporated in the running buffer, all other highly 
active test compounds (IC50 < 50 μmol L–1) resulted in a similar kind of shift in the migra-
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Fig. 3. Detailed view of the docked pose of tested drugs and the corresponding interacting amino acid 
moieties within the binding site of pancreatic lipase enzyme (code: A = GzD, B = GsA, C = CsA, D = 
OrP, E = DnS, F = AsA and G = SfD). IC50 value and estimated Chemguass score are shown on the right 
and left of each compound, resp. 
Key to net version: green H- bonding; pale green weaker H-bonding; pink, pale pink and orange are 
all hydrophobic interactions.
13
I. I. Hamdan et al.: Pancreatic lipase inhibitory activity of selected pharmaceutical agents, Acta Pharm. 69 (2019) 1–16.
 
tion time of PL (regardless of their charge) although to various degrees. Though small, the 
observed shift is most likely a result of the conformational changes induced by the in-
hibitor binding rather than a non-specific effect caused by the incorporation of the drug in 
the running buffer. Moreover, when both the test drug and OsT were incorporated in the 
running buffer, the change in tm and peak shape was larger than that observed in the case 
of the test drug or OsT alone, except for DnS. Namely, addition of OsT to the running buffer 
containing DnS did not bring about any further change in the tm of PL. For other test drugs, 
including OrP, SfD and GzD, addition of OsT to the running buffer containing the test drug 
was shown to result in an additional change in tm (Fig. 4). The obtained experimental data 
are in accord with the hypotheses proposed above, where OsT could bind to PL along with 
other test drugs but not with DnS, with consequent observed synergism with other test 
compounds but not with DnS. Our findings are the first to suggest a potential synergistic 
inhibitory effect of two PL binding agents (inhibitors). Along this line, we propose further 
optimization of the test drugs using the highly promising fragment based drug design ap-
proach that has been shown successful in a number of cases, particularly when two mo-
lecular fragments show a synergistic effect (31, 32). Fragment based drug optimization suits 
our test compounds in particular because many of them showed modest inhibitory activity 
that was synergistically enhanced with the standard PL inhibitor OsT.
Fig. 4. Representative electropherograms of PL in phosphate buffer (pH 6.8): a) alone, b) with both OrP 
and OsT, c) with OrP, d) with OsT, e) with DnS, f) with both DnS and OsT. Note the change of tm of PL 
from 5.6 min (in a) to 6.5 min (in e and f).
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CONCLUSIONS
A considerable number of commonly used pharmaceutical compounds were shown 
to have significant PL inhibitory activity. The most effective PL inhibitory compounds 
included dinitro salicylic acid (DnS), camphor sulphonic acid (CsA), gliclazide (GzD), 
gama-anilino sulfonic acid (GsA) and orphenadrine (OrP). An algorithm that reasonably 
described the correlation between the observed inhibitory activity and structural param-
eters could be found. According to the correlation equation comprising pKa, log P, molecu-
lar surface area and molecular complexity, two linear relationships could be distinguished 
reflecting the two major modes of inhibitions caused by two groups of compounds. While 
one of the mechanisms was through the usual inhibition by binding to the enzyme active 
site, the other that described the activity of the lower activity compounds appeared to be 
achieved at least in part through surface activity. Inhibitory activity test in the presence of 
both the test drug and OsT revealed synergistic and antagonistic action of various tested 
drugs with OsT. Most interesting perhaps was the observation that some compounds with 
little activity demonstrated a significant synergistic effect with OsT. On the other hand, 
DnS, the compound with the lowest IC50 value, appeared to have some antagonistic effect 
with OsT rather than synergism. 
Docking studies revealed the ability of test compounds to bind to the active site in a 
similar manner to that of the well-known standard inhibitors. While GzD and GsA did not 
show significant binding to the amino acid having the decisive role in the inhibitory effect 
of PL (Ser-152), they showed strong interactions through different residues that provided 
the highest Chemgauss scores as calculated by the software. Therefore, molecules which 
did not interact with Ser-152, the most important residue in PL, exhibited the lowest in vitro 
inhibitory activity among the list of highest ranking active compounds. In addition, such 
compounds appeared to allow for co-binding of OsT to the binding site, resulting in en-
hanced inhibitory activity. Other compounds which exhibited ability to strongly interact 
with the binding site (Ser-152 in particular) did not seem to allow for co-binding of OsT 
and thus they had an antagonistic rather than synergistic effect. Further studies are needed, 
perhaps using crystallography, to further confirm the occurrence of co-binding to the 
enzyme. We highly recommend the use of the compounds investigated in this study in 
fragment-based drug design to build up and potentially reach new ceilings of PL inhibi-
tory activities.
Abbreviations, acronyms, symbols. – ACE – affinity capillary electrophoresis, AsA – acetylsalicylic 
acid, AsP – aspartic acid, AvS – atorvastatin, AzN – azithromycin, CfA – cefuroxime axetil, CpL – 
cephalexin, CsA – camphor sulfonic acid, DbS – diethylbarbituric acid, DcS – diclofenac sodium, 
DMSO – dimethyl suloxide, DnS – dinitro salicylic acid, DoS – sodium dioctylsulfonate, e-gram – 
electropherogram, EOF – electroosmotic flow, GbP – gabapentin, GsA – gamma-anilino naphthalene 
sulfonic acid, GzD – gliclazide, LnP – lansoprazole, LrP – losartan potassium, MfA – mefenamic acid, 
MnZ – metronidazole, OrP – orphenadrine, OsT – orlistat, PL – pancreatic lipase, PNPB – p-nitrophe-
nyl butyrate, PrL – propranolol, PsE – pseudoephedrine, ScA – salicylic acid, SdS – sodium dodecyl 
sulfate, SfD – sulfacetamide, UrA – uric acid.
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